Literature DB >> 24855534

Thromoboagiitis Obliterans (TAO).

Ui-Jun Park1, Dong-Ik Kim1.   

Abstract

Thromboangiitis obliterans (TAO) is nonatherosclerotic inflammatory disease of the peripheral blood vessels, and TAO affects the small and medium sized vessels of the extremities. TAO is mainly seen in young males who smoke, and smoking is strongly associated with the disease course and progression. The diagnosis is made on the basis of the history, the physical examination and the clinical diagnostic criteria. As the bedrock for treating patients with TAO, absolute abstinence from tobacco is most important factor, and patients with TAO are usually managed conservatively. Surgical bypass or endovascular therapy is usually not possible for patients with TAO because of the diffuse segmental involvement and the distal nature of the disease. Therefore, stem cell therapy is considered to be a novel therapeutic modality for treating patients with TAO and who are not eligible for conventional revascularization therapies. In this paper, I have summarized the recent knowledge about TAO and I have reviewed the recent studies that have focused on the treatment of TAO.

Entities:  

Keywords:  Angiogenesis; Stem cells; Thromboangiitis obliterans

Year:  2010        PMID: 24855534      PMCID: PMC4022683          DOI: 10.15283/ijsc.2010.3.1.1

Source DB:  PubMed          Journal:  Int J Stem Cells        ISSN: 2005-3606            Impact factor:   2.500


  61 in total

1.  Buerger's disease and cigarette smoking in Bangladesh.

Authors:  W J Grove; G P Stansby
Journal:  Ann R Coll Surg Engl       Date:  1992-03       Impact factor: 1.891

Review 2.  Collateral artery growth: making the most of what you have.

Authors:  Stéphanie Lehoux; Bernard I Lévy
Journal:  Circ Res       Date:  2006-09-15       Impact factor: 17.367

3.  Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease.

Authors:  Dong-Ik Kim; Mi-Jung Kim; Jin-Hyun Joh; Sung-Wook Shin; Young-Soo Do; Ji-Young Moon; Na-Ri Kim; Joung-Eun Lim; Ae-Kyeong Kim; Hyun-Seon Eo; Byung-Soo Kim; Seung-Woo Cho; Seung-Hye Yang; Chan-Jeoung Park; Jong-Sup Shim
Journal:  Stem Cells       Date:  2006-01-26       Impact factor: 6.277

4.  Current trends in thromboangiitis obliterans (Buerger's disease) in women.

Authors:  S Sasaki; M Sakuma; T Kunihara; K Yasuda
Journal:  Am J Surg       Date:  1999-04       Impact factor: 2.565

5.  Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.

Authors:  Pingping Huang; Shangzhu Li; Mingzhe Han; Zhijian Xiao; Renchi Yang; Zhong Chao Han
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

Review 6.  Buerger's disease in the 21st century: diagnosis, clinical features, and therapy.

Authors:  Joseph L Mills
Journal:  Semin Vasc Surg       Date:  2003-09       Impact factor: 1.000

7.  Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group.

Authors: 
Journal:  Eur J Vasc Endovasc Surg       Date:  1998-04       Impact factor: 7.069

8.  Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans.

Authors:  Ping Ping Huang; Xiao Feng Yang; Shan Zhu Li; Jin Chao Wen; Yan Zhang; Zhong Chao Han
Journal:  Thromb Haemost       Date:  2007-12       Impact factor: 5.249

9.  Involvement of the coronary artery in a patient with thromboangiitis obliterans. A case report.

Authors:  Necip Becit; Yahya Unlü; Hikmet Koçak; Münacettin Ceviz
Journal:  Heart Vessels       Date:  2002-07       Impact factor: 2.037

10.  Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia.

Authors:  Satoaki Matoba; Tetsuya Tatsumi; Toyoaki Murohara; Tsutomu Imaizumi; Yousuke Katsuda; Masaaki Ito; Yoshihiko Saito; Shiro Uemura; Hiroshi Suzuki; Shinya Fukumoto; Yasutaka Yamamoto; Rie Onodera; Satoshi Teramukai; Masanori Fukushima; Hiroaki Matsubara
Journal:  Am Heart J       Date:  2008-09-19       Impact factor: 4.749

View more
  5 in total

1.  A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial Assessing the Safety and Efficacy of Intramuscular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Severe Buerger's Disease.

Authors:  Jeong Chan Ra; Euicheol C Jeong; Sung Keun Kang; Seog Ju Lee; Kyoung Ho Choi
Journal:  Cell Med       Date:  2016-10-03

Review 2.  Differentiation of hESCs into Mesodermal Subtypes: Vascular-, Hematopoietic- and Mesenchymal-lineage Cells.

Authors:  Sung-Hwan Moon; Jung Mo Kim; Ki-Sung Hong; Jeong Min Shin; Jumi Kim; Hyung-Min Chung
Journal:  Int J Stem Cells       Date:  2011-06       Impact factor: 2.500

3.  Ten year outcomes after bypass surgery in aortoiliac occlusive disease.

Authors:  Gwan-Chul Lee; Shin-Seok Yang; Keun-Myoung Park; Yangjin Park; Young-Wook Kim; Kwang Bo Park; Hong Suk Park; Young-Soo Do; Dong-Ik Kim
Journal:  J Korean Surg Soc       Date:  2012-05-29

4.  Comparisons between prosthetic vascular graft and saphenous vein graft in femoro-popliteal bypass.

Authors:  Keun-Myoung Park; Young Wook Kim; Shin-Seok Yang; Dong-Ik Kim
Journal:  Ann Surg Treat Res       Date:  2014-06-24       Impact factor: 1.859

5.  Long Term Outcomes of Femorofemoral Crossover Bypass Grafts.

Authors:  Keun-Myoung Park; Yang-Jin Park; Young-Wook Kim; Dongho Hyun; Kwang Bo Park; Young-Soo Do; Dong-Ik Kim
Journal:  Vasc Specialist Int       Date:  2017-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.